NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy

Cancer Letters

Volumn 278, Issue 2, 2009, Pages 145-155

  Wu, Jian Min ^a   Sheng, Hongmiao ^a   Saxena, Romil ^a   Skill, Nicholas James ^a   Bhat Nakshatri, Poornima ^a   Yu, Menggang ^a   Nakshatri, Harikrishna ^a   Maluccio, Mary A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatocellular carcinoma (HCC); NF B; Sorafenib; Therapy

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN P65; MATRIX METALLOPROTEINASE 14; PROTEIN MCL 1; SORAFENIB; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; I KAPPA B; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEIN BCL 2; PYRIDINE DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL DEATH; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; APOPTOSIS; CANCER INVASION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; I-KAPPA B PROTEINS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 64649087510     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.031     Document Type: Article

References (26)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25 (2005) 143-154
2. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Int. Med. 139 (2003) 817-823
3. Naugler W.E., and Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18 (2008) 19-26
4. Schomer-Miller B., Higashimoto T., Lee Y.K., and Zandi E. Regulation of IkappaB kinase (IKK) complex by IKKgamma-dependent phosphorylation of the T-loop and C terminus of IKKbeta. J. Biol. Chem. 281 (2006) 15268-15276
5. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
6. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
7. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
8. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
9. Coleman W.B. Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med. 3 (2003) 573-588
10. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., and Rong H. Et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
11. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98 (2006) 326-334
12. Newton T.R., Patel N.M., Bhat-Nakshatri P., Stauss C.R., Goulet Jr R.J., and Nakshatri H. Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells. J. Biol. Chem. 274 (1999) 18827-18835
13. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
14. Delhase M., Hayakawa M., Chen Y., and Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 284 (1999) 309-313
15. Ralstin M.C., Gage E.A., Yip-Schneider M.T., Klein P.J., Wiebke E.A., and Schmidt C.M. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol. Cancer Res. 6 (2006) 387-399
16. Liotta L.A., and Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51 (1991) 5054-5059
17. Arii S., Mise M., Harada T., Furutani M., Ishigami S., Niwano M., et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24 (1996) 316-322
18. Théret N., Musso O., Turlin B., Lotrian D., Bioulac-Sage P., Campion J.P., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34 (2001) 82-88
19. Ip Y.C., Cheung S.T., and Fan S.T. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol. Carcinogen. 46 (2007) 225-230
20. Poon R.T., Fan S.T., Ng I.O., Lo C.M., Liu C.L., and Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89 (2000) 500-507
21. Bogenrieder T., and Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22 (2003) 6524-6536
22. Yao D.F., Wu X.H., Zhu Y., Shi G.S., Dong Z.Z., Yao D.B., et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4 (2005) 220-226
23. Jane E.P., Premkumar D.R., and Pollack I.F. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. 319 (2006) 1070-1080
24. Yu C., Friday B.B., Lai J.P., Yang L., Sarkaria J., Kay N.E., et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 5 (2006) 2378-2387
25. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65 (2005) 2412-2421
26. Elsharkawy A.M., and Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46 (2007) 590-597